Evidence-Based Medicine’s Success May Alter Definition Of Proprietary Data
This article was originally published in The Gray Sheet
Executive Summary
With more emphasis being placed on the use of clinical evidence to drive insurance coverage and treatment decisions, providers' information needs may force manufacturers to change their views on proprietary data
You may also be interested in...
House Bill Targets Imaging Payments To Help Fund Children’s Insurance
A rapidly moving Medicare bill puts imaging payments back in the crosshairs as the House looks for cost-saving measures to fund coverage of uninsured children and prevent massive cuts to physician payments
Public Registration Of Device Trials Increases 10-Fold In Two Years
Registration of medical device trials on a government Web site increased more than 10-fold in the past two years, and legislation moving through Congress is likely to expand that activity even further
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.